Skip to main content
HitGen Inc. logo

HitGen Inc. — Investor Relations & Filings

Ticker · 688222 ISIN · CNE1000040G3 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 629 across all filing types
Latest filing 2023-10-11 Major Shareholding Noti…
Country CN China
Listing Shanghai Stock Exchange 688222

About HitGen Inc.

https://www.hitgen.com/en

HitGen Inc. is a technology-driven research and development organization focused on the discovery of novel small molecule drug candidates. The company leverages its proprietary DNA-encoded library (DEL) platform, which features a collection of over 1.2 trillion diverse small molecules, to enable efficient hit identification and lead optimization. HitGen offers integrated drug discovery services, incorporating fragment-based drug discovery (FBDD) and structure-based drug design through its specialized research facilities. Its core operations include collaborative research partnerships with global pharmaceutical entities and the development of an internal pipeline of therapeutic programs. The platform combines synthetic chemistry, biology, and data informatics to streamline the identification of bioactive compounds for complex therapeutic targets.

Recent filings

Filing Released Lang Actions
成都先导药物开发股份有限公司关于持股5%以上股东权益变动超过1%的提示性公告
Major Shareholding Notification Classification · 100% confidence The document is a notification about a change in shareholding by a shareholder holding more than 5% of the company's shares. It details the shareholding percentages before and after the change, the shareholder's identity, and confirms that the change does not affect control or governance. The document is titled as a "提示性公告" (prompting announcement) regarding shareholding changes exceeding 1%. It does not contain financial statements or detailed financial analysis but is a regulatory disclosure about major shareholding changes. Therefore, it fits the category of Major Shareholding Notification (MRQ). The document length is short and focused solely on shareholding changes, confirming this classification.
2023-10-11 Chinese
成都先导药物开发股份有限公司关于股东减持计划时间届满暨减持结果公告
Major Shareholding Notification Classification · 95% confidence The document is a formal announcement from Chengdu Lead Drug Development Co., Ltd. regarding the completion and results of a shareholder share reduction plan. It details the shareholders involved, the number of shares held before and after the reduction, the reduction period, methods, prices, and amounts. The document is not a financial report, earnings release, or management discussion but a disclosure about shareholding changes due to share sales by shareholders. This fits the category of Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels. The document length is 2090 characters, and it is a detailed announcement of shareholding changes, not a report publication or regulatory filing. Therefore, the correct classification is MRQ with high confidence.
2023-09-28 Chinese
成都先导药物开发股份有限公司关于获得政府补助的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (459 characters) about the company receiving a government subsidy. It includes basic information about the subsidy amount, its expected impact on profits, and a disclaimer that the subsidy has not been audited yet. There is no detailed financial data, no full report, and no mention of an annual or interim report. The document is an announcement of a financial event rather than a full financial report or detailed management discussion. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is a regulatory announcement about a government subsidy, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2023-09-28 Chinese
成都先导药物开发股份有限公司2023年限制性股票激励计划激励对象名单（授予日）
Board/Management Information Classification · 95% confidence The document is titled as a list of incentive recipients under a 2023 restricted stock incentive plan by Chengdu Lead Drug Development Co., Ltd. It details the allocation of restricted stock to senior management, core technical personnel, and other incentivized individuals. The document is essentially an announcement of the incentive plan participants and their stock allocations, which relates to management and board decisions about stock incentives. There is no financial statement, audit, or detailed report content. The document length is 4456 characters, which is relatively short and more consistent with an announcement rather than a full report. This type of document fits best under 'Board/Management Information (MANG)' as it concerns management incentives and stock awards, which are typically disclosed as board-related announcements.
2023-09-07 Chinese
成都先导药物开发股份有限公司第二届监事会第十次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Chengdu Lead Drug Development Co., Ltd. regarding the approval of a restricted stock incentive plan. It details the meeting date, attendance, and the decision to grant restricted shares to incentive recipients. The document does not contain financial statements or detailed financial data but is an official announcement of a board meeting decision related to management and governance matters. It is not an annual report, audit report, earnings release, or any other financial report. It fits best under Board/Management Information (MANG) as it relates to a supervisory board meeting resolution and governance decisions about stock incentives.
2023-09-07 Chinese
成都先导药物开发股份有限公司独立董事关于第二届董事会第十二次会议相关议案的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on proposals related to the company's board meeting held on September 7, 2023. It discusses the approval of a restricted stock incentive plan, compliance with regulatory requirements, and governance benefits. The document is short (893 characters) and focuses on board-related opinions rather than full financial data or detailed reports. It is not a full annual or interim report, nor an earnings release or audit report. It is also not a simple announcement of a report publication. The content fits best under Board/Management Information (MANG) as it relates to board meeting decisions and governance matters regarding stock incentives.
2023-09-07 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.